Equine mesenchymal stromal cells from different tissue sources display comparable immune-related gene expression profiles in response to interferon gamma (IFN)-γ.
Abstract: Mesenchymal stromal cells (MSC) have the therapeutic potential to decrease inflammation due to their immunomodulatory properties. They can be isolated from various tissue sources such as bone marrow, adipose tissue, and blood, but it is unknown how the tissue source of origin affects the responses of MSC to inflammatory stimuli. Here, we conceptually addressed this question by evaluating the immune-related gene expression profiles of equine MSC from different tissue sources in response to interferon gamma (IFN-γ) stimulation, with the goal to determine if there is a preferable MSC source for clinical application in an inflammatory environment. The salient findings from this initial study were that the baseline expression of all immune related genes analyzed, with the exception of prostaglandin-endoperoxide synthase 2 (PTGS2), was variable in MSC depending on tissue source. Following IFN-γ stimulation, however, gene expression profiles became more similar across all tissue sources, suggesting that MSC from different sources will likely respond similarly in an inflammatory environment when used clinically.
Copyright © 2018 Elsevier B.V. All rights reserved.
Publication Date: 2018-06-11 PubMed ID: 30078595DOI: 10.1016/j.vetimm.2018.06.008Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article examines how mesenchymal stromal cells (MSC), derived from different tissues in horses, respond at a genetic level to an inflammatory stimulus, Interferon Gamma (IFN-γ). The study aims to establish whether the source of these cells impacts their therapeutic usefulness in reducing inflammation.
Background and Objectives
- The researchers aim to understand how the source of MSC affects their immunomodulatory properties, specifically their response to an inflammatory trigger, IFN-γ.
- They experiment with MSC from different sources – bone marrow, adipose tissue, and blood, as each of these has been established as a reliable source for isolating these cells.
- The ultimate objective of the study is to identify whether a specific source of MSC is superior for clinical application in treating inflammation.
Methodology
- To perform the study, they isolated MSC from different tissue sources of horses and stimulated them with IFN-γ.
- They then examined changes in the expression of immune-related genes in these MSC post-stimulation, tracking which genes were being expressed more or less vigorously as a result of the stimulus.
Key Findings
- The study concluded that the base-level expression of all immune-related genes, except one (prostaglandin-endoperoxide synthase 2 or PTGS2), varied depending on the tissue source of the MSC.
- However, once the cells were stimulated with IFN-γ, these differences reduced considerably, leading to a ‘stabilization’ or standardization of gene expression profiles across MSC from all sources.
Implications
- The findings suggest that, contrary to initial expectations, the tissue source of MSC does not significantly impact their response to inflammatory stimuli. This means the therapeutic potential of MSC in reducing inflammation remains consistent irrespective of their tissue origin.
- This can simplify the process of sourcing MSC for therapeutic purposes in equine medicine, since the response to inflammation is a key aspect of their healing and reparative properties.
Cite This Article
APA
Cassano JM, Fortier LA, Hicks RB, Harman RM, Van de Walle GR.
(2018).
Equine mesenchymal stromal cells from different tissue sources display comparable immune-related gene expression profiles in response to interferon gamma (IFN)-γ.
Vet Immunol Immunopathol, 202, 25-30.
https://doi.org/10.1016/j.vetimm.2018.06.008 Publication
Researcher Affiliations
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14850, USA. Electronic address: jmc292@cornell.edu.
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14850, USA. Electronic address: laf4@cornell.edu.
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14850, USA. Electronic address: rbh232@cornell.edu.
- Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14850, USA. Electronic address: rmh12@cornell.edu.
- Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14850, USA. Electronic address: grv23@cornell.edu.
MeSH Terms
- Animals
- Cell Differentiation / genetics
- Cell Proliferation
- Cells, Cultured
- Cyclooxygenase 2 / genetics
- Cyclooxygenase 2 / immunology
- Horses / immunology
- Immunomodulation
- Inflammation / veterinary
- Interferon-gamma / pharmacology
- Mesenchymal Stem Cells / drug effects
- Mesenchymal Stem Cells / immunology
- Transcriptome
Citations
This article has been cited 8 times.- Jammes M, Contentin R, Cassé F, Galéra P. Equine osteoarthritis: Strategies to enhance mesenchymal stromal cell-based acellular therapies.. Front Vet Sci 2023;10:1115774.
- Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.. Front Vet Sci 2022;9:957153.
- Yasamineh S, Kalajahi HG, Yasamineh P, Gholizadeh O, Youshanlouei HR, Matloub SK, Mozafari M, Jokar E, Yazdani Y, Dadashpour M. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.. Stem Cell Res Ther 2022 Jun 17;13(1):257.
- Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.. Animals (Basel) 2022 Apr 11;12(8).
- Shahsavari A, Weeratunga P, Ovchinnikov DA, Whitworth DJ. Pluripotency and immunomodulatory signatures of canine induced pluripotent stem cell-derived mesenchymal stromal cells are similar to harvested mesenchymal stromal cells.. Sci Rep 2021 Feb 10;11(1):3486.
- Gugjoo MB, Hussain S, Amarpal, Shah RA, Dhama K. Mesenchymal Stem Cell-Mediated Immuno-Modulatory and Anti- Inflammatory Mechanisms in Immune and Allergic Disorders.. Recent Pat Inflamm Allergy Drug Discov 2020;14(1):3-14.
- Hillmann A, Paebst F, Brehm W, Piehler D, Schubert S, Tárnok A, Burk J. A novel direct co-culture assay analyzed by multicolor flow cytometry reveals context- and cell type-specific immunomodulatory effects of equine mesenchymal stromal cells.. PLoS One 2019;14(6):e0218949.
- Myneni VD, McClain-Caldwell I, Martin D, Vitale-Cross L, Marko K, Firriolo JM, Labow BI, Mezey E. Mesenchymal stromal cells from infants with simple polydactyly modulate immune responses more efficiently than adult mesenchymal stromal cells.. Cytotherapy 2019 Feb;21(2):148-161.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
